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Abstract
Cell permeable peptides (CPP) aid cellular uptake of targeted cargo across the hydrophobic plasma membrane.
CPP-mediated cargo delivery of receptor signaling motifs provides an opportunity to regulate specific receptor
initiated signaling cascades. Both endothelin-1 receptors, ETA and ETB, have been targets of antagonist therapies
for individuals with pulmonary arterial hypertension (PAH). These therapies have had success but have been
accompanied by adverse reactions. Also, unlike the CPP which target specific signaling cascades, the antagonists
target the entire function of the receptor. Using the CPP strategy of biased antagonism of the ETB receptor’s
intracellular loop 2 (ICB2), we demonstrate blunting of hypoxic pulmonary hypertension (HPH) in the rat, including
indices of pulmonary arterial pressure, right ventricular hypertrophy and pulmonary vascular remodeling. Further, ex
vivo analysis of the pulmonary artery treated with the IC2B peptide upon injection manifests marked reductions in Akt
and ERK activation. Both kinases have been intimately related to cell proliferation and vascular contraction, the
hallmarks of PAH. These observations in sum illustrate an involvement of the ETB receptor in HPH and furthermore
provide a basis for a novel, CPP-based, strategy in the treatment of PAH, ultimately able to target not only ET-1, but
also other factors involved in the development of PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a disease of
multiple etiologies and high morbidity and mortality,
characterized by elevated pulmonary artery pressure, cellular
proliferation in the pulmonary vasculature with formation of
plexiform lesions and right heart hypertrophy and eventually,
failure [1]. Concomitant with aberrant cell growth is
dysregulation of the G-protein coupled receptors (GPCR) for
endothelin-1, ETA and ETB [2]. Individuals with PAH also have
increased plasma endothelin-1 (ET-1) levels which further
contribute to a contracted state and remodeling of vessels
within the lung [3]. The ETA and ETB receptors are therapeutic
targets for the dual acting antagonist, bosentan [4]. However,
the role of the ETB receptor in the pathogenesis of PAH is not
clear. ETB has been shown to mediate vasoconstriction, while
certain aspects of ETB action have actually been reported as
physiologically beneficial [5-8]. Thus, we sought to determine
whether targeted antagonism of ETB signaling in an
experimental model has a net inhibitory or contributory effect
on the development of pulmonary hypertension.
There are several rodent models of hypoxic pulmonary
hypertension (HPH) including monocrotaline as well as chronic
hypoxia [9,10]. The hypoxic model has been well-defined with a
major component of sustained pulmonary vasoconstriction,
combined with structural pulmonary vascular remodeling,
leading to chronic elevation of pulmonary arterial pressures
and right ventricular hypertrophy [11]. ET-1 plays a role in the
pathogenesis of this model of HPH and, in some studies, the
ETB receptor has been shown to have ameliorating effects
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[12]. Which signaling cascade(s) are most important in the
induction or continuation of HPH or clinical PAH has not yet
been established. Akt and ERK have been reported to
participate in animal models of HPH [13]. Akt in isolated
smooth muscle cells promotes hypertrophy, proliferation and
cell survival [14-16]. ERK has also been shown to promote
smooth muscle contraction and proliferation [17]. Therefore, it
was important to determine whether our targeted blocking of
the IC2 region of the ETB receptor not only influences the
development of HPH, but also modifies the activation of these
two kinases.
In addition to traditional pharmacological approaches,
modulation of the signaling properties of G-protein coupled
receptors has also been approached through the use of cell
permeable peptides (CPP). CPP are short peptide sequences
that can freely cross cell membranes and can facilitate the
translocation of various molecular cargos [18]. The ability to
transport peptide cargos across the cell membrane provides an
opportunity to create peptide motifs which mask, or mimic,
functional motifs of GPCRs [19,20]. The effect of CPP is similar
to that of biased agonists or antagonists, but does not require
interference with ligand binding or receptor internalization. To
promote membrane permeability and facilitate internalization, a
critical design feature is the use of a SynB3 [21] based-CPP
design named SynB3RG. The SynB transporter sequence was
derived from protegrin (the SynB peptide vectors), which
possess enhanced drug-transport ability across the blood-brain
barrier [22]. The mechanism of the SynB cargo delivery system
is considered to be an adsorptive-mediated endocytosis
process [22].
In the present study, we use the hypoxic rat model to
determine whether HPH can be attenuated by interfering with
Figure 1.  Uptake of 5-FAM tagged IC2B peptide into pulmonary artery smooth muscle cells.  The chemical structure of
SynB3RG transporter sequence attached to IC2 loop of the ETB receptor is illustrated in (A). Flow cytometry shows that 5-FAM
tagged IC2B peptide entered the cells efficiently after 20 mins of exposure (B).
doi: 10.1371/journal.pone.0081309.g001
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ET-1 signal transmission through the second intracellular loop
of the ETB receptor. This targeted approach allows us to
determine the contribution of the ETB receptor to the
development of HPH and whether early Akt and ERK signals
are concomitantly altered by the CPP.
Materials and Methods
Animals
Male Sprague-Dawley rats (250-275) were obtained from
Taconic Labs (Boston, MA, USA). The Tufts IACUC Committee
approved all animal studies. For hypoxic exposures, rats were
put in normobaric hypoxia (FIO2 10.5%) or similar normoxic
chambers (for controls) for 3 weeks or 24 hr while given
intraperitoneal injections of peptide or vehicle injections on day
one and weekly thereafter. For a detailed description of the
animal procedures see Hypoxia Model and Experimental
Design in the Methods S1.
Synthesis of CPP (IC2B)
For a detailed description of the synthesis of IC2B peptide
see Methods S1.
Determination of Peptide Cell Penetration
5-FAM (5-Carboxyfluorescein) tagged IC2B (IC2B-FAM)
peptide (10 uM) in serum-free media was added to pulmonary
artery smooth muscle cell cultures grown in 6 well plates. After
30 min at 37°C, to cleave adhering CPP from the cell
membranes and to detach the cells from the wells, the cells
were washed twice with PBS and then trypsinized and
resuspended in PBS as a single cell suspension. The single
cell suspension was transferred into tubes at a concentration of
1.5 X 106 cells per ml. Cells were analyzed by flow cytometry
on a FacsCalibur (BectonDickinson, Franklin Lakes, NJ). A
total of 10,000 gated cells per sample were counted. Data were
analyzed using Cytomation Summit software (Cytomation Inc.,
Fort Collins, USA). As controls, cells were incubated with
peptide-free medium.
Determination of IC2B peptide Cell Penetration in the
isolated Pulmonary Artery
Pulmonary arteries were isolated from adult rats (250-275 g)
washed in sterile HBSS twice. The vessels were then cut open
so as to allow maximum exposure of the internal and external
vessel to the peptide. The vessels were then exposed to 5-
FAM tagged IC2B peptide (10 uM) in HBSS without phenol red
for 1 hr at 37°C in the dark. Control vessels were placed in the
same media without the 5-FAM tagged IC2B peptide. Following
Figure 2.  Penetrance of 5-FAM tagged IC2B peptide into rat pulmonary artery tissue.  Ex vivo vessel tissues were imaged
with a fluorescence microscope at 40X magnification after treating with medium containing 5-FAM tagged IC2B peptide (A) or sham
(B) for 1 hr. In vivo penetrance was determined by taking images of normal rat lung with no injected IC2B-FAM (C), a lung from a rat
IP injected with the IC2B 5-FAM (D,E). Arrows show staining of SMC in airways and large vessels (D) and small arterioles (E).
doi: 10.1371/journal.pone.0081309.g002
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exposure the vessels were washed in fresh HBSS twice and
placed in 4% NBF overnight then paraffin embedded and 5 um
sections made. Sections were viewed on Zeiss (Thornwood,
NY) fluorescence microscope and images recorded.
Determination of IC2B peptide Cell Penetration in vivo
5-FAM tagged IC2B peptide (10 uM) was administered IP,
following 2 hours the animal was sacrificed and the lungs
inflated with OCT and then frozen. Cryosections were made,
observed and recorded on Zeiss fluorescence microscope
Histological Analysis of Pulmonary Artery
Morphological analysis was done following lung fixation and
embedding. Transverse sections, 5 um were cut from left lung
midzones of paraffin-mounted lungs. Sections were stained
with van Gieson elastic stain. Vessels below 125 um diameter
were examined. Vessels were graded as none (<25%), partial
(25%-75%), and fully (>75%) muscularized. Fifty vessels per
slide were graded by readers blinded to the experimental
group.
Ex Vivo Pulmonary Artery Kinase Signaling
The pulmonary artery was isolated from treated and control
animals, cut into 2 mm rings and placed in cold serum-free
DMEM on ice. By carefuly clearing the vessel slices (rings) of
any remaining adventitia or intima we insured that the rings
consisted principally of smooth muscle. Three to four rings
were placed in 24 well plates with pre-warmed serum-free
DMEM and incubated as described in the figure legends.
Following incubation the rings were washed with cold PBS,
placed in cryogenic vials, and immediately snap frozen in liquid
nitrogen. The frozen vials were stored at –80°C. For western
blotting, the rings were thawed on ice in 100 ul of RIPA buffer
with protease and phosphatase inhibitors included to maintain
the generated phosphorylated proteins. The rings were then
dissociated on ice using 17 gauge needles. After dissociation,
the samples were centrifuged at 10,000 RPM for 30 min at 4°C
and the supernatant was used for western blotting procedures.
Figure 3.  Effect of the IC2B peptide on right ventricular systolic pressure (RSVP) in hypoxic rats.  Rats were treated with
hypoxia or room air for 3 weeks while given injections of peptide or saline on day one and weekly thereafter. Data are means + SEM
N=6-10 per group .
* P<0.05 vs hypoxic saline.
doi: 10.1371/journal.pone.0081309.g003
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Western Blotting
Protein concentrations were determined by BCA method.
SDS-PAGE was run with 4% stacking gels and 10% separating
gels. SDS-PAGE separations were transferred on nitrocellulose
membranes (BioRad, Hercules, CA) at 100 V and 4°C for 1 h.
Membranes were washed 3 times for about 5 min with TBS-T
(20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6), blocked
at room T for 1 h with 5% powdered milk in TBS-T, washed
again 3 times, for 5 min, and incubated in 1° rabbit antibody at
4°C overnight in 1:1000 phospho-p44/p42 MAPK Thr202/
Tyr204 (pERK) (#9101), 1:2000 phospho-Akt Ser473 (pAkt)
(#4060), 1:1000 total Akt (tAkt) (#9272) or 1:1000 total ERK
(tERK) (#9102) dilutions plus 5% BSA in TBS-T. All 1°
antibodies were purchased from Cell Signaling Technologies
(Cell Signaling, Danvers, MA). Blots were washed again in
TBS-T followed by 1 h incubation in the corresponding anti-
rabbit 2° Ab (Santa Cruz Biotechnology, Santa Cruz, CA)
diluted 1:10,000 TBS-T. Blots were then washed 3 times in
TTBS-T, and developed in detection reagents from Thermo
Scientific (Rockford, IL) for 1 min before exposure to
autoradiography film. Densitometry on band intensities was
performed using the NIH ImageJ image analysis software.
Statistics
Mean values were calculated for each group of rats.
Differences in mean values between normoxic and hypoxic
animals were compared by two-way ANOVA. Where significant
differences were observed, pairwise comparisons were done
using the Student–Newman-Keuls method. Differences in
percent muscularization of pulmonary vessels were analyzed
by proportion comparison and Yates correction. Data are
expressed as means + SEM. Differences were considered
significant at P<0.05. Statistical analysis was done using
SigmaStat (Systat, Point Richmond CA).
Results
Cellular and tissue penetration of the CPP Molecule
A CPP mimetic of the IC2 loop of the ETB receptor is drawn
schematically in Figure 1A. As illustrated, the IC2 loop of the
Figure 4.  Effect of the IC2B peptide on hypertrophy in hypoxic rats.  Rats were treated with hypoxia or room air for 3 weeks
while given injections of peptide or saline on day one and weekly thereafter. Hypertrophy was calculated by the right ventricular / left
ventricle + septum (RV/LV+S) ratios. Data are means + SEM N=6-10 per group * P<0.05 vs hypoxic saline.
doi: 10.1371/journal.pone.0081309.g004
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ETB receptor was attached to the SynB3RG transporter
sequence using a lysine side-chain introduced at its C-terminus
(Figure 1A) and termed IC2B. To test the ability of the IC2B to
penetrate cells a FAM labeled-derivative was synthesized
termed IC2B-FAM. The FAM label was introduced at the side
chain of the lysine residue of the SynB3R component of the
ligand (Figure 1A). Pulmonary artery smooth muscle cells
incubated with the IC2B-FAM were analyzed for fluorescence
using flow cytometry. Results are illustrated in Figure 1B. The
IC2B-FAM was efficiently inserted into cells within twenty
minutes. Tissue penetration of the IC2B was also tested in
intact rat pulmonary arteries. Pulmonary arteries after excision
were incubated with IC2B-FAM at 10 mM for 20 minutes.
Strong fluorescence is seen in the presence of IC2B-FAM
whereas little to no fluorescence, indicative of
autofluorescence, is seen in control vessels (Figure 2A,B). The
layers of fluorescence in the treated vessels appear to be
smooth muscle. Following an IP injection, the IC2B, attached to
FAM also penetrates the lung vasculature and is highly
selective for smooth muscle cells including the large and small
pulmonary arteries as illustrated in Figure 2C,D,E.
Hypoxia and the physiologic effect of the IC2B CPP
The rat hypoxia model of PAH was used as described in the
Methods section. After 3 weeks of exposure hypoxic rats
treated with the IC2B peptide showed a significant decrease in
the right ventricular systolic pressure (RVSP) vs. saline treated
hypoxic controls (48.6+2.7 vs 59.1+4.8 p=0.029) (Figure 3).
Right ventricular pressures were similar in both the IC2B
peptide and control normoxic animals, indicating no effect of
the peptide in normoxic animals. Furthermore, as shown in
Figure 4, there was reduced hypertrophy in the IC2B peptide
treated hypoxic right ventricle as measured by RV/LV+S
compared with RVs from saline-treated hypoxic controls
(0.398+.021 vs 0.483+.025 p=.005). Systolic and diastolic
systemic blood pressure was unaffected by treatment with the
IC2B or hypoxia; nor was there any statistically significant
difference in cardiac index or LV+S/BW among the groups
(Table 1). Although not statistically significant and not
associated with any alteration in RVSP, there was a slightly
lower cardiac index in the normoxic rats treated with the IC2B.
Histological analysis of small pulmonary vessels
Normoxic saline-treated and IC2B-treated animals displayed
no significant differences in percent muscularization of small
pulmonary vessels (Figure 5). The hypoxic animals treated with
saline showed the typical response of a significant increase in
fully muscularized vessels versus the normoxic groups.
Between the hypoxic groups, the IC2B-treated vessels had
significantly blunted increases in per cent fully muscularized
vessels compared to saline controls.
Toxicology of IC2B
Body weights of both hypoxic groups were significantly less
than normoxic rats, but there was no significant difference
between the IC2B groups and their respective controls, nor
was there evidence of extremity edema or ascites, suggesting
that IC2B did not induce fluid retention. Analysis of standard
liver function studies as well as blood urea nitrogen showed no
evidence of hepatorenal toxicity attributable to IC2B. Aspartate
aminotransferase increased with exposure to hypoxia
compared to normoxic rats, but no further change occurred
with 3 weeks’ administration of the IC2B peptide (Table 2).
Effect of IC2B on ETB receptor promoted kinase
activation during hypoxia
Using the same protocol for the hypoxic experiments as
above, rats were subjected to hypoxia for 24h in the presence
or absence of injected IC2B peptide. After the 24h exposure,
pulmonary arteries were excised and ERK and Akt activation
was determined in tissue slices. Hypoxia increased the levels
of both phosphorylated ERK and Akt in pulmonary artery slices
from hypoxic compared to normoxic rats (Figure 6A). Other
slices were treated with BQ123, an antagonist of ET-1 binding
to the ETA receptor, as a means of focusing on the action of
the ETB receptor. This inhibitor was formerly shown to block
over 90% of ETA promoted ERK activation while not affecting
ETB promoted signaling [2]. Under these conditions, as
illustrated in Figure 6B,C,D, ET-1 markedly activated Akt and
ERK in pulmonary arteries (as determined by the ratio of
phosphorylated to total protein) from rats subjected to hypoxia.
This activation was markedly blunted by the IC2B peptide.
Discussion
The principal aim of this study was to examine the possibility
that a CPP blocking a narrower signaling segment of a receptor
than that of a receptor antagonist could be used as a means to
study the mechanisms of PAH as well as a potential
therapeutic target for this disease. Within this aim we elected to
Table 1. Body weight (BW), systemic blood pressure (systolic and diastolic), and left ventricle + septum/ body weight (LV+
+S/BW) of rats exposed to 3 weeks hypoxia or room air and injected with IC2B peptide or saline.
 BW (g) Systolic (mm Hg) Diastolic (mm Hg) Cardiac Index (ml/min/kg) LV+S/BW
Normoxic Saline 350 + 16 135 + 4 105 + 5 190 + 12 2.17 + 0.04
Normoxic IC2B 373 + 14 134 + 5 100 + 6 142 + 4 2.17 + 0.09
Hypoxic Saline 311 + 5* 142 + 4 115 + 3 205 + 39 2.04 + 0.05
Hypoxic IC2B 315 + 4* 155 + 4 123 + 3 198 + 19 2.14 + 0.09
Data are means + SEM N=6-10 per group * P<0.05 vs normoxic
doi: 10.1371/journal.pone.0081309.t001
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focus on the actions of the ETB receptor in a rat model of
pulmonary hypertension. Prior work has identified the ETA
receptor as the principal ET-1 contributor to the pathology of
PAH, while the role of ETB has been far less understood.
Currently, available endothelin-1 receptor antagonists are dual
receptor blockers. These have provided therapeutic benefits.
However this treatment has come at a cost because the
antagonists, with their wide-ranging blocking effects, have
Figure 5.  Effect of the IC2B peptide on vessel muscularization.  Percentage of peripheral pulmonary vessels that were fully,
partial, or nonmuscularized (none) of rats exposed to 3 weeks hypoxia or room air and injected with IC2B peptide or placebo. Data
are means + SEM N=6-10 per group * P<0.05 vs hypoxic saline full.
doi: 10.1371/journal.pone.0081309.g005
Table 2. Blood indices to assess for hepatorenal toxicity of IC2B.
 Normoxic Hypoxic Hypoxic + CPP
Alkaline Phosphatase 179 + 20 195 + 31 176 + 16
ALT 25 + 4 30 + 10 33 + 6
AST 48 + 3 73 + 8 * 81 + 8 *
Creatine Kinase 163 + 46 236 + 90 225 + 38
GGT 2.0 + 0.0 3.0 + 0.0 2.4 + 0.6
Albumin 2.9 + 0.1 2.9 + 0.2 2.8 + 0.1
Total Protein 5.6 + 0.2 5.2 + 0.2 5.0 + 0.1
Total Bilirubin 0.1 + 0.0 0.1 + 0.0 0.1 + 0.0
Blood Urea Nitrogen 18.8 + 2.8 26.3 + 8.4 20.0 + 2.2
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransaminase; GGT = gamma glutamyl transpeptidase. *p < 0.05 vs normoxic.
doi: 10.1371/journal.pone.0081309.t002
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adverse side effects including liver toxicity and fluid retention
[23]. Based on these toxic effects, targeted modulation of ETB
receptor signaling, rather than its entire blockade, would
provide a novel and interesting approach toward the treatment
of pulmonary hypertension. It would also provide insight into
the role of ETB in HPH pathogenesis. In previous studies we
showed that CPP-mimicking motifs within the intracellular faces
of GPCR can alter signal cascades by such vasoactive
effectors as angiotensin and endothelin-1 [19,20].. Here, we
synthesized a CPP containing a copy of the intracellular
second loop of the ETB receptor.
Deciphering the contribution of the ETB receptor to the
pathogenesis of pulmonary hypertension has been complicated
by the fact that both vasodilatory and vasoconstrictor actions
have been ascribed to it [24]. Prior studies on the role of the
ETB receptor in rodent pulmonary hypertension have
demonstrated an exacerbation of pulmonary hypertension in
the spotting-lethal rat, which carries a deletion of ETB, in both
the hypoxic [25] and monocrotaline [26] PAH models. More
recently, similar findings have been reported in mice genetically
deficient in the ETB receptor when exposed to hypoxia [27].
Our approach to receptor blockade is very different than the
genetic deletion approach used in the earlier rodent studies.
Figure 6.  Effect of the IC2B peptide on pulmonary artery Akt and ERK signaling.  Rats were treated with hypoxia and injected
with IC2B peptide for 24 h. Pulmonary artery rings were isolated and pre-incubated with or without 1uM BQ123 for 30 mins. Then,
the rings were treated with or without 10 nM ET-1 for 20 min. Protein lysates were probed for pAkt, pERK, tAkt and tERK. Western
blot analysis comparing basal pAkt and pERK levels in pulmonary artery rings from normoxic and hypoxic rats (A). Western blot
analysis of rat pulmonary artery rings from hypoxic rats injected with the IC2B peptide (B). Bar graphs illustrate the densitometric
ratios of pAkt (C) and pERK (D) normalized to tAkt and tERK, respectively. Blots are representative of triplicate experiments. Data
are means + SEM N=3 * P<0.05 vs hypoxic control. # P<0.05 vs hypoxic ET-1 plus BQ123. a.u=arbitrary unit.
doi: 10.1371/journal.pone.0081309.g006
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Targeting of limited signal cascades confers specificity of
blockade and provides an opportunity to target deleterious
actions while leaving desirable receptor effects intact, such as
the ET-1 clearance function of ETB. Also, our
immunofluorescent studies on pulmonary arterial distribution of
the IC2B in both ex vivo and in vivo preparations suggest that it
penetrates cells in the vascular media where the ETB may
have important vasoconstrictive/proliferative effects.
Using the hypoxic rat model of PAH, we showed that the
presence of the IC2B ameliorated the development of HPH.
We found that this peptide hindered ET-1 promoted ERK and
Akt phosphorylation in rat pulmonary artery smooth muscle.
These two kinases are important participants in vascular
hypertrophy and both are upregulated in HPH [28]. We also
demonstrated in the hypoxic rat model of PAH that the peptide
mitigates PAH manifestations. Specifically, the IC2B
significantly decreased right ventricular systolic pressure and
right ventricular hypertrophy. Histologic examination of the
small pulmonary vessels of hypoxic animals showed that the
IC2B also significantly decreased fully muscularized vessels
compared to controls. The protective effects were pulmonary
selective since there was no reduction in systemic pressures.
These findings illustrate that, in this model, the ETB receptor
does indeed contribute to the pathogenesis of HPH.
Additionally, we demonstrate that CPPs may have therapeutic
potential for pulmonary hypertension.
Our results are surprising considering other previous studies
which indicated that a blockade of the ETB receptor
exacerbates pulmonary hypertension in rodent models (25-27).
This suggests that blockade of specific signaling components
of the ETB receptor may have different physiologic effects. For
example, it has long been known that the ETB receptor in
endothelial cells promotes release of vasodilators such as nitric
oxide [29] and clears circulating ET1 [30]. The IC2B could
leave these functions intact while blocking the vasoconstrictor
actions mediated by the ETB receptor on smooth muscle cells,
thus ameliorating hypoxic pulmonary hypertension, as we
observed.
Our study has some limitations. While the IC2B clearly
mitigates HPH manifestations, the dosage and frequency of
injection may not have been optimal. Future studies on
pharmacokinetics of the CPPs will be necessary to optimize
these factors. Also, although the imunohistochemistry studies
we performed demonstrate staining of vascular media, our
methods did not permit differentiation of IC2B actions on
smooth muscle cells vs endothelial cells. Further, our signaling
studies are based on observations from more proximal
pulmonary arteries and may vary from the distal resistance
vessels which we were unable to dissect from intact lungs due
to technical limitations. In the same context, while we focused
our signaling determinations on tissue rings containing the
media by meticulously scraping off the adventitia and intima a
very small fraction of endothelial and fibroblastic cells may
have remained in the rings.
In conclusion, our findings indicate that CPPs are capable of
specific physiologic blockade, such as the vasoconstrictor
actions of the ETB receptor. Thus, unlike treatment with
standard pharmacologic receptor antagonists which block the
entire receptor action regardless of beneficial or deleterious
actions, the CPP approach can be much more specifically
targeted at deleterious actions and could well avoid off-target
organ toxicity. However, ET-1 and its ETB receptor are only
components of a number of other molecular contributors to the
etiology of PAH. Clearly, realizing the therapeutic potential of
CPPs will require considerably more work and possibly
targeting of multiple pathways simultaneously in future studies
of these molecules.
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